Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans and examine the risk factors for intensive care unit (ICU) admission and ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

Some States Reporting a Dramatic Rise in RSV: Here's What You Need to Know About the Respiratory Virus Young children and adults over 65, or those with chronic illnesses, are at a high risk of ...

RSV and the flu are separate viruses that both cause respiratory infections. Both viruses tend to become more active in the winter, but the flu remained much more active last season in comparison ...

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.